As life expectancy increases globally, clinicians encounter complex neurodegenerative disorders that frequently co-exist in the aging brain. Multiple neuropathological lesions accumulate over decades, including amyloid deposition, tau tangles, alpha-synuclein aggregates, and microvascular damage. However, the precise molecular mechanisms distinguishing these concurrent processes remain challenging to identify. Recent transcriptomic research highlights the regulatory importance of small non-coding molecules in cerebral aging. In particular, profiling reveals that brain microRNAs exhibit distinctive expression patterns across multiple age-associated cerebral lesions. Deciphering these epigenetic alterations provides essential biological clarity for differentiating mixed neuropathologies in aging individuals.

Understanding the Complex Landscape of Brain MicroRNAs

MicroRNAs represent small non-coding RNA molecules that regulate post-transcriptional gene expression across diverse cellular pathways. Consequently, they modulate vital neurobiological processes, including synaptic plasticity, neuroinflammation, cellular transport, and neuronal survival. In the aging central nervous system, dysregulation of brain microRNAs disrupts physiological homeostasis and promotes pathological vulnerability. A landmark genomic study evaluated microRNA sequencing profiles from the dorsolateral prefrontal cortex of 617 human brain donors. Initially, the investigators adjusted their analytical models for essential demographic variables, including age, sex, and educational attainment. As a result, they identified significant transcriptomic alterations across five major age-related neuropathologies. These pathologies included Alzheimer's, Lewy bodies, arteriolosclerosis, cerebral amyloid angiopathy, and LATE-NC. Because older patients frequently develop multiple concurrent lesions, unadjusted analyses often generate confounding associations. Therefore, the researchers incorporated advanced multivariable adjustments to account for co-existing cerebral pathologies. This rigorous statistical framework successfully separated disease-specific transcriptomic signatures from shared non-specific epiphenomena, establishing a robust foundation for future mechanistic discoveries.

Differentiating Pathology-Specific MicroRNA Signatures

After adjusting for co-occurring cerebral pathologies, the researchers identified distinct microRNA signatures uniquely linked to individual disease states. For example, Alzheimer's disease pathology demonstrated independent associations with 75 specific microRNAs within the dorsolateral prefrontal cortex. Furthermore, Lewy body pathology displayed specific associations with 45 unique microRNAs. In contrast, vascular and TDP-43 pathologies exhibited substantially fewer private molecular alterations. Specifically, arteriolosclerosis correlated with three microRNAs, whereas cerebral amyloid angiopathy linked to only one specific microRNA. Additionally, limbic-predominant age-related TDP-43 encephalopathy neuropathologic change maintained independent associations with four microRNAs. These noticeable numerical disparities suggest that parenchymal proteinopathies drive widespread transcriptomic remodeling in cortical tissue. Conversely, microvascular lesions and localized protein inclusions provoke more restricted epigenetic shifts in the frontal cortex. Moreover, identifying pathology-specific transcripts facilitates the discovery of reliable clinical biomarkers with enhanced diagnostic accuracy. Clinicians frequently encounter diagnostic dilemmas when evaluating overlapping dementia syndromes. Consequently, mapping isolated microRNA alterations provides crucial molecular markers to differentiate Alzheimer's disease from Lewy body dementia and vascular cognitive impairment.

Shared MicroRNA Networks in Alzheimer's and Lewy Body Pathologies

Although several microRNAs exhibited strict disease specificity, the investigators discovered notable molecular convergence between major neurodegenerative diseases. Specifically, 14 microRNAs demonstrated simultaneous associations with both Alzheimer's disease and Lewy body pathology after adjusting for co-existing lesions. Most notably, members of the well-characterized miR-132/212 cluster emerged as shared down-regulated regulators across both conditions. Previous preclinical studies demonstrate that loss of the miR-132/212 cluster impairs tau phosphorylation and accelerates toxic amyloid-beta accumulation. Furthermore, this regulatory cluster maintains synaptic communication and promotes adult neurogenesis in vulnerable cortical regions. Therefore, down-regulation of miR-132/212 may foster a permissive environment that facilitates both alpha-synuclein and tau protein aggregation. Additionally, the researchers identified that miR-193a-5p associated concurrently with Alzheimer's disease pathology and cerebral amyloid angiopathy. This shared association indicates a critical mechanistic bridge linking parenchymal amyloid deposition with cerebrovascular amyloid angiopathy. Consequently, therapeutic strategies targeting common microRNA nodes could potentially address multiple neuropathological cascades simultaneously. Because mixed pathology represents the dominant presentation in elderly patients, these shared epigenetic networks offer compelling opportunities for multi-target neuroprotective interventions.

Microvascular Pathways in Arteriolosclerosis and Cerebral Amyloid Angiopathy

Cerebrovascular dysfunction represents a major driver of cognitive decline and vascular dementia in aging populations. To elucidate underlying vascular mechanisms, the investigators conducted gene set enrichment analyses for microRNAs linked to arteriolosclerosis. Interestingly, target genes for these arteriolosclerosis-associated microRNAs participate actively in glutathione metabolism, synaptic functioning, cellular transport, and innate immune responses. Glutathione pathways provide critical antioxidant protection for cerebral endothelial cells and mural pericytes. Consequently, epigenetic dysregulation of glutathione metabolism elevates oxidative stress, compromises blood-brain barrier stability, and provokes arteriolosclerotic vessel remodeling. Furthermore, impaired cellular transport and chronic innate immune activation accelerate perivascular inflammation and subcortical ischemic injury. In parallel, cerebral amyloid angiopathy demonstrated specific dysregulation of miR-193a-5p, which governs vascular matrix remodeling and amyloid clearance. Clinicians frequently observe that vascular risk factors worsen cognitive outcomes in patients with neurodegenerative diseases. Therefore, these transcriptomic findings emphasize the clinical necessity of aggressive vascular risk control. By mitigating microvascular oxidative damage, clinicians can preserve neurovascular coupling and attenuate downstream neurodegenerative progression.

Clinical Implications and Future Diagnostic Directions

These transcriptomic discoveries provide valuable clinical insights for practicing neurologists, geriatricians, and internists managing cognitive disorders. Currently, clinical evaluations rely upon neurocognitive testing, neuroimaging, and cerebrospinal fluid biomarkers to detect neurodegeneration. However, existing diagnostic tools often fail to capture the complex contributions of co-existing cerebral pathologies in living patients. By establishing rigorous microRNA expression profiles from 617 donors, this research outlines practical pathways for biomarker development. In the future, circulating extracellular vesicles carrying brain microRNAs could provide accessible, non-invasive liquid biopsies. Consequently, clinicians might soon utilize blood tests to identify occult Lewy body pathology or cerebral arteriolosclerosis before severe dementia manifests. Furthermore, synthetic microRNA mimics and antagomiRs offer promising therapeutic avenues for restoring epigenetic balance. Because individual microRNAs modulate coordinated gene networks, targeted therapeutics could modify disease trajectory across multiple pathological cascades. Nevertheless, clinical translation requires rigorous validation across diverse, multi-ethnic patient populations. Healthcare providers should closely follow these advancements, as non-coding RNA profiling will substantially refine diagnostic precision and personalized neurotherapeutics.

Frequently Asked Questions

What role do brain microRNAs play in neurodegenerative pathologies?

Brain microRNAs regulate post-transcriptional gene expression across critical central nervous system pathways. They maintain synaptic plasticity, control cellular transport, modulate neuroinflammation, and preserve mitochondrial function. Pathological disruption of microRNA expression increases neuronal vulnerability. Consequently, toxic protein aggregation, oxidative stress, and cell death accelerate across neurodegenerative disorders.

Why is adjusting for co-existing cerebral pathologies critical?

Older individuals frequently develop multiple brain pathologies simultaneously, including amyloid plaques, Lewy bodies, and microvascular arteriolosclerosis. Without adjusting for concurrent lesions, statistical models misattribute shared molecular changes to a single disease. Multivariable adjustment isolates true disease-specific microRNA signatures. As a result, researchers ensure accurate biological and clinical interpretation.

How might these microRNA profiles inform clinical practice in the future?

These microRNA profiles provide valuable targets for diagnostic biomarkers and novel therapeutics. Because brain-derived microRNAs cross the blood-brain barrier via extracellular vesicles, clinicians might soon measure them through routine blood tests. Furthermore, restoring depleted microRNAs or blocking overexpressed transcripts could halt neurodegeneration across multiple co-occurring cerebral pathologies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Refer to the latest local and national guidelines for clinical practice.

References

1. Luo T et al. Brain microRNAs differentially expressed in age-related cerebral pathologies. Neurobiol Aging. 2025 Jul. doi: 10.1016/j.neurobiolaging.2025.03.014. PMID: 40228357.


2. Pichler S, Gu W, Hartl D, et al. The miRNome of Alzheimer's disease: consistent downregulation of the miR-132/212 cluster. Neurobiol Aging. 2017;50:167.e1-167.e10.


3. Hébert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis. 2013;35(2):335-348.